Exclusive Online Content
Cambrex Invests in Generic API Development & Manufacturing Capabilities at its Milan Site
Cambrex Corporation, the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), recently announced that it has made a number of investments,…
Aptar Pharma Showcase its Premium Injectables Portfolio
Aptar Pharma, a leading drug delivery systems provider, will showcase the latest developments in its Premium injectables portfolio when it exhibits at Parenteral Drug Association’s…
Amgen-Backed Immatics Lands $58 Million to Develop T-Cell Receptor-Based Immunotherapies
Immatics, a leading company in the field of cancer immunotherapy, recently announced the completion of its Series E financing, raising $58 million. The Series E…
KemPharm & Genco Sciences Announce Technology Licensing Agreement
KemPharm, Inc., a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, recently announced it has entered into a technology licensing…
Achieve Life Science Announces Advancement of Cytisine Clinical Development Program
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, recently announced the commencement of…
American Heart Association's New Scientific Statement Deems the Corus CAD Test Valid & Useful for Clinicians Evaluating Obstructive CAD
CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, recently announced today in a Scientific Statement by the American Heart Association, the Corus® CAD…
Roivant Sciences Launches Datavant to Improve Clinical Trials With Artificial Intelligence
Roivant Sciences recently announced the launch of Datavant, a new company focused on employing artificial intelligence to improve the clinical trial process. Datavant will be…
Catalent to Acquire Cook Pharmica for $950 Million
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, recently announced it has…
DFB Pharmaceuticals Forms NanOlogy & Soria for Clinical Development of Naked Nanoparticle Platform
Demand for new cancer drugs is enormous with public and private investment skyrocketing for new technologies. Immunotherapies have captured much of the attention in recent…
APAC Drug Delivery Devices Market to Reach $5.4 Billion in 2023
Drug delivery devices market in Asia Pacific (India, China, Japan, South Korea, Australia, New Zealand, and Taiwan) region is expected to grow at CAGR 3.9%,…
AMRI Expands Sterile Production Capacity
AMRI, a global contract research, development and manufacturing organization, is expanding its sterile manufacturing capacity. The addition of an aseptic pre-filled syringe filling line at…
GSK Exercises Option Over Adaptimmune’s SPEAR T-Cell Therapy Program
Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, recently announced that GlaxoSmithKline plc has exercised its option under a collaboration and license…
Novartis AG Receives First Ever FDA Approval for CAR-T
A new era in cancer treatment is now here. The US FDA recently gave the nod to Switzerland-based Novartis AG for its gene therapy cancer…
Huber Closes $630-Million Sale of Silica Business to Evonik
The J.M. Huber Corporation has completed the sale of the Silica business unit of Huber Engineered Materials (HEM) to Evonik Industries AG, a global specialty…
Roquette Completes Acquisition, Reinforces Ambition of Being Excipient Leader
Roquette, a global leader in innovative plant-based ingredients, recently announced it has completed the acquisition of Itacel from Blanver. Itacel is a leading player…
Dr. Christian Fischer to Succeed Uwe Röhrhoff as CEO of Gerresheimer AG
With effect from September 1, 2017, Dr. Christian Fischer (53) is to assume responsibility as Chief Executive Officer of Gerresheimer AG. He succeeds Uwe Röhrhoff…
Novartis Injection Could Prevent Heart Attacks, Slash Cancer Risk
By Ben Spencer, Medical Correspondent Thousands of lives could be saved thanks to a new heart drug hailed as the biggest breakthrough since…
Ajinomoto Althea, Inc. Announces New Aseptic Fill Finish Line
Ajinomoto Althea, a leading service provider of biopharmaceutical contract development and manufacturing drug programs, announces the installation and launch of a new high-performance sterile…
Cardiovascular Disease - Innovation Within Dyslipidemia, Heart Failure & Thrombosis Set to Reduce High CVD Mortality Rate
With over 1,400 products in active development, the innovation pipeline for cardiovascular disease (CVD) is extensive, with four key CVD indications – hypertension,…
Manufacturing Process Scale-Up for Phase III: Clear Sailing or Storms Ahead?
Some drug developers diligently design scalability into their formulations from day one and are fully prepared for larger-scale production during Phase III. Essentially, their only…
